scholarly journals Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review

2018 ◽  
Vol 93 (11) ◽  
pp. 1629-1647 ◽  
Author(s):  
Salvatore Carbone ◽  
Dave L. Dixon ◽  
Leo F. Buckley ◽  
Antonio Abbate
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
State Of The Art ◽  
Cardiovascular Risk Reduction ◽  
Glucose Lowering

Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

2017 ◽  
Vol 31 (4) ◽  
pp. 459-470 ◽  
Author(s):  
Scott L. Purga ◽  
Mandeep Sidhu ◽  
Michael Farkouh ◽  
Joshua Schulman-Marcus
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Cardiovascular Risk Reduction

scholarly journals LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST

2018 ◽  
pp. 89-92
Author(s):  
S. V. Nedogoda
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Pleiotropic Effect ◽  
Successful Management ◽  
Cardiovascular Risk Reduction ◽  
Glucose Lowering

The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®).

Sign in / Sign up

Export Citation Format

Share Document